All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the EHA2021 Virtual Congress, the AML Hub spoke with Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, Should pre-transplant measurable residual disease (MRD) be used to guide treatment in AML?
Should pre-transplant MRD be used to guide treatment in AML?
Nagler begins by discussing the importance of MRD in AML treatment and transplantation. He highlights the significance of MRD in different settings as a prognosis factor and describes the result of his study presented at EHA2021. Finally, he outlines the current treatment landscape for transplants in relation to MRD status and makes recommendations for MRD-positive patients.
Subscribe to get the best content related to AML delivered to your inbox